<p><strong>公司持续扩大领先的伤口产品供应</strong></p>
<p>乔治亚州马里埃塔，2025 年 12 月 22 日（GLOBE NEWSWIRE）-- MiMedx Group, Inc.（纳斯达克：MDXG）（“MIMEDX” 或 “公司”）今天宣布已与 Regen Lab USA LLC 签署独家协议，在美国分销其 RegenKit®-伤口凝胶。</p>
<p>RegenKit®-伤口凝胶是一种自体富血小板血浆（PRP）和自体凝血酶血清（ATS）伤口凝胶，能够去除含铁的红血球，同时在自然纤维蛋白支架中浓缩必需的生长因子、功能性血小板、血浆蛋白和细胞营养物质。这种完全自体的解决方案为公司的先进伤口护理产品组合增加了一个差异化的选择，并得到了多项已发表研究的支持，这些研究评估了其在治疗慢性伤口方面的有效性。RegenKit®-伤口凝胶套件由 Antoine Turzi 开发，并于 2022 年获得 FDA 批准，已被 CMS 和 LCD 在全国范围内覆盖，用于根据 HCPCS 代码 G0465 治疗糖尿病慢性伤口。</p>
<p>“随着 RegenKit 的加入，我们正在继续扩大我们的伤口护理产品组合，为患者和医疗专业人员提供一系列经过验证的解决方案，” MIMEDX 首席商业官 Kim Moller 表示。“我们很高兴能为我们的产品提供一个自体选项，并预计这将成为我们不断扩展的伤口产品系列中一个高度互补的补充。该协议，加上最近宣布的关于 2026 年 1 月 1 日地方覆盖决定（LCD）实施的明确性，使 MIMEDX 在进入新的一年时处于一个极具竞争力的强势地位。”</p>
<p><strong>关于 Regen Lab USA LLC.</strong></p>
<p>Regen Lab USA LLC.是一家位于美国新泽西州泽西市的自体再生医学领导者。该公司于 2003 年由 Antoine Turzi 创立，专注于设计和制造高质量的医疗设备，用于细胞治疗和从患者自身血液中制备自体 PRP 以进行床边操作。</p>
<p><strong>关于 MIMEDX</strong></p>
<p>MIMEDX 是一家专注于帮助人类愈合的先锋和领导者。凭借十多年的帮助临床医生管理慢性和其他难以愈合的伤口的经验，MIMEDX 提供了一系列领先的产品，应用于伤口护理、烧伤和外科医疗领域。公司的愿景是通过不断创新成为全球领先的愈合解决方案提供商，以恢复生活质量。有关更多信息，请访问 www.mimedx.com。</p>
<p><strong>联系方式：</strong></p>
<p>Matt Notarianni</p>
<p>投资者关系</p>
<p>470-304-7291</p>
<p>mnotarianni@mimedx.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5UazVOQ00zTXpNek1EYzJJekl3TVRBMU56Zz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5UazVOQ00zTXpNek1EYzJJekl3TVRBMU56Zz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZjVlOTI2ZGMtY2RlOC00MzQzLWI0ZTItZDAzZWUxYzg4ZDQ2LTEwMjIxNTEtMjAyNS0xMi0yMi1lbg==/tiny/MiMedx-Group-Inc.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZjVlOTI2ZGMtY2RlOC00MzQzLWI0ZTItZDAzZWUxYzg4ZDQ2LTEwMjIxNTEtMjAyNS0xMi0yMi1lbg==/tiny/MiMedx-Group-Inc.png"/></p>

MDXG

<p>MIMEDX Group, Inc. 与 Regen Lab USA LLC 签署了独家美国分销协议，涉及 RegenKit®-Wound Gel，增强了其先进伤口护理产品组合。该凝胶于 2022 年获得 FDA 批准，用于治疗慢性伤口，并受到 CMS 和 LCD 的覆盖。此协议巩固了 MIMEDX 在伤口护理市场的竞争地位</p>

<p><strong>Company Continues to Broaden Leading Wound Product Offering</strong></p>
<div class="lb-trans"><p><strong>公司持续扩大领先的伤口产品供应</strong></p>
</div><p>MARIETTA, Ga., Dec. 22, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it has entered into an exclusive agreement with Regen Lab USA LLC to distribute their RegenKit®-Wound Gel in the United States.</p>
<div class="lb-trans"><p>乔治亚州马里埃塔，2025 年 12 月 22 日（GLOBE NEWSWIRE）-- MiMedx Group, Inc.（纳斯达克：MDXG）（“MIMEDX” 或 “公司”）今天宣布已与 Regen Lab USA LLC 签署独家协议，在美国分销其 RegenKit®-伤口凝胶。</p>
</div><p>RegenKit®-Wound Gel is an autologous platelet-rich plasma (PRP) and autologous thrombin serum (ATS) wound gel that removes iron-laden red blood cells, while concentrating essential growth factors, functional platelets, plasma proteins, and cellular nutrients in a natural fibrin scaffold. The fully autologous solution adds a differentiated option to the Company’s Advanced Wound Care portfolio and is backed by multiple published studies evaluating its effectiveness in treating chronic wounds. RegenKit®-Wound Gel kits, developed by Antoine Turzi and approved by FDA in 2022, are covered nationally by CMS and LCD for the treatment of diabetic chronic wounds under HCPCS code G0465.</p>
<div class="lb-trans"><p>RegenKit®-伤口凝胶是一种自体富血小板血浆（PRP）和自体凝血酶血清（ATS）伤口凝胶，能够去除含铁的红血球，同时在自然纤维蛋白支架中浓缩必需的生长因子、功能性血小板、血浆蛋白和细胞营养物质。这种完全自体的解决方案为公司的先进伤口护理产品组合增加了一个差异化的选择，并得到了多项已发表研究的支持，这些研究评估了其在治疗慢性伤口方面的有效性。RegenKit®-伤口凝胶套件由 Antoine Turzi 开发，并于 2022 年获得 FDA 批准，已被 CMS 和 LCD 在全国范围内覆盖，用于根据 HCPCS 代码 G0465 治疗糖尿病慢性伤口。</p>
</div><p>“With the addition of RegenKit, we are continuing to broaden our portfolio in Wound Care to offer patients and healthcare professionals an extensive assortment of proven solutions,” stated Kim Moller, MIMEDX Chief Commercial Officer. “We are excited to add an autologous option to our offering, and we expect it will prove to be a highly complementary addition to our expanding suite of Wound products. This agreement, in combination with the recently announced clarity on Local Coverage Determination (LCD) implementation on Jan 1, 2026, puts MIMEDX in an incredibly strong competitive position as we prepare to enter the new year.”</p>
<div class="lb-trans"><p>“随着 RegenKit 的加入，我们正在继续扩大我们的伤口护理产品组合，为患者和医疗专业人员提供一系列经过验证的解决方案，” MIMEDX 首席商业官 Kim Moller 表示。“我们很高兴能为我们的产品提供一个自体选项，并预计这将成为我们不断扩展的伤口产品系列中一个高度互补的补充。该协议，加上最近宣布的关于 2026 年 1 月 1 日地方覆盖决定（LCD）实施的明确性，使 MIMEDX 在进入新的一年时处于一个极具竞争力的强势地位。”</p>
</div><p><strong>About Regen Lab USA LLC.</strong></p>
<div class="lb-trans"><p><strong>关于 Regen Lab USA LLC.</strong></p>
</div><p>Regen Lab USA LLC. is a leader in autologous regenerative medicine based in Jersey City, New Jersey, USA. Founded in 2003 by Antoine Turzi, Regen Lab is specialized in designing and manufacturing high-quality medical devices for cell therapies and the preparation of autologous PRP from the patient's own blood for bedside procedures.</p>
<div class="lb-trans"><p>Regen Lab USA LLC.是一家位于美国新泽西州泽西市的自体再生医学领导者。该公司于 2003 年由 Antoine Turzi 创立，专注于设计和制造高质量的医疗设备，用于细胞治疗和从患者自身血液中制备自体 PRP 以进行床边操作。</p>
</div><p><strong>About MIMEDX</strong></p>
<div class="lb-trans"><p><strong>关于 MIMEDX</strong></p>
</div><p>MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.</p>
<div class="lb-trans"><p>MIMEDX 是一家专注于帮助人类愈合的先锋和领导者。凭借十多年的帮助临床医生管理慢性和其他难以愈合的伤口的经验，MIMEDX 提供了一系列领先的产品，应用于伤口护理、烧伤和外科医疗领域。公司的愿景是通过不断创新成为全球领先的愈合解决方案提供商，以恢复生活质量。有关更多信息，请访问 www.mimedx.com。</p>
</div><p><strong>Contact:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p>Matt Notarianni</p>
<div class="lb-trans"><p>Matt Notarianni</p>
</div><p>Investor Relations</p>
<div class="lb-trans"><p>投资者关系</p>
</div><p>470-304-7291</p>
<div class="lb-trans"><p>470-304-7291</p>
</div><p>mnotarianni@mimedx.com</p>
<div class="lb-trans"><p>mnotarianni@mimedx.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5UazVOQ00zTXpNek1EYzJJekl3TVRBMU56Zz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYxNTk5NCM3MzMzMDc2IzIwMTA1Nzg="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZjVlOTI2ZGMtY2RlOC00MzQzLWI0ZTItZDAzZWUxYzg4ZDQ2LTEwMjIxNTEtMjAyNS0xMi0yMi1lbg==/tiny/MiMedx-Group-Inc.png" alt="" original-src="https://ml.globenewswire.com/media/ZjVlOTI2ZGMtY2RlOC00MzQzLWI0ZTItZDAzZWUxYzg4ZDQ2LTEwMjIxNTEtMjAyNS0xMi0yMi1lbg==/tiny/MiMedx-Group-Inc.png"/></p>

MiMedx 与 RegenKit®-伤口凝胶签署美国独家分销协议 | MDXG 股票新闻